{
    "Clinical Trial ID": "NCT01806259",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Ketorolac 30 mg",
        "  Active drug to be compared with placebo",
        "Ketorolac 30 mg IV",
        "INTERVENTION 2: ",
        "  NaCl 0.9% 3mL",
        "Ketorolac 30 mg IV"
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Written informed Consent age : 18-85 years weight: 50-100 kg Neutrophils / Lymphocytes ratio >4 and/or \"triple negative\" histological status and/or Positive lymph nodes",
        "Exclusion Criteria:",
        "  Previous cancer (behalf of basocellular skin cancer and in situ uterine cervix cancer) Non compliance or refusal of the protocol Positive Pregnancy test Childbearing or breastfeeding mothers Contra-indication for NSAIDs NSAIDs intake in the 5 days before randomisation NSAIDs use planned in the 30 days after randomisation Non curative surgery (T4 or M1 tumor classification )"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Recurrence-free Survival",
        "  2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years)",
        "  Time frame: 5 years",
        "Results 1: ",
        "  Arm/Group Title: Ketorolac 30 mg",
        "  Arm/Group Description: Active drug to be compared with placebo",
        "  Ketorolac 30 mg IV",
        "  Overall Number of Participants Analyzed: 96",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  80  83.3%",
        "Results 2: ",
        "  Arm/Group Title: NaCl 0.9% 3mL",
        "  Arm/Group Description: Ketorolac 30 mg IV",
        "  Overall Number of Participants Analyzed: 107",
        "  Measure Type: Count of Participants",
        "  Unit of Measure: Participants  96  89.7%"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 8/96 (8.33%)",
        "  Hematoma requiring surgery  1/96 (1.04%)",
        "  Any type (not bleeding related)  7/96 (7.29%)",
        "Adverse Events 2:",
        "  Total: 7/107 (6.54%)",
        "  Hematoma requiring surgery  0/107 (0.00%)",
        "  Any type (not bleeding related)  7/107 (6.54%)"
    ]
}